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Background: Heparin Binding Protein (HBP) is released to blood circulation from activated neutrophils in bacterial
infections. It is a potential inducer of vascular leakage and precludes the development of septic shock. Filgrastim
induces the production of new neutrophils and modulates their bacterial-killing activity. We evaluated the effect of
filgrastim on HBP –concentrations in critically ill patients with acute respiratory failure.
Methods: 59 critically ill patients with acute respiratory failure were included in this randomised, double-blind,
placebo-controlled study of filgrastim 300 micrograms/day or corresponding placebo for 7 days. Plasma samples
were drawn on baseline, day 4 and day 7. HBP –concentrations, absolute leukocyte and neutrophil counts were
measured.
Results: The median [IQR] HBP concentrations were 23.6 ng/ml [13.9-43.0 ng/ml], 25.1 ng/ml [17.7-35.5 ng/ml] and
15.9 ng/ml [12.6-20.7 ng/ml] in patients receiving filgrastim on baseline, day 4 and day 7, respectively. The HBP
concentrations in placebo group were 21.6 ng/ml [16.9-28.7 ng/ml], 13.9 ng/ml [12.0-19.5 ng/ml] and 17.8 ng/ml
[13.6-20.9 ng/ml]. At day 4, the filgrastim group had significantly higher HBP –concentrations when compared to
placebo group (p < 0.05). No correlation between HBP –concentrations and absolute neutrophil count or P/F –ratios
was found.
Conclusions: Filgrastim treatment is associated with increased circulating HBP levels compared to placebo, but the
absolute neutrophil count or the degree of oxygenation failure did not correlate with the observed plasma HBP –
concentrations.
Trial registration: Clinicaltrials.gov NCT01713309
Keywords: Filgrastim, G-CSF, Heparin-binding protein, Critically ill, Acute respiratory failure* Correspondence: maija.kaukonen@monash.edu
1Intensive Care Unit, Helsinki University Central Hospital, Helsinki, Finland
2ANZIC Research Centre, Department of Epidemiology and Preventative
Medicine, School of Public Health & Preventive Medicine, Monash University,
Melbourne, Australia
Full list of author information is available at the end of the article
© 2013 Kaukonen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kaukonen et al. BMC Infectious Diseases 2013, 13:51 Page 2 of 6
http://www.biomedcentral.com/1471-2334/13/51Background
Plasma leakage from the vasculature is an important
step in the development of septic shock in patients with
infections [1]. Heparin binding protein (HBP; also
known as azurocidin and CAP37) is an immunomodula-
tory mediator released from activated neutrophils [2].
The release of HBP is stimulated e.g. when neutrophils
adhere to the endothelial lining or when these cells en-
counter bacterial products in the circulation. The
released HBP initiates rearrangement of the endothelial
cell cytoskeleton, leading to openings in the endothelial
barrier and increased macromolecular leakage to inter-
stitial space [3]. This is an important mechanism of un-
controllable leakage in inflammatory conditions.
In capillary leakage such as septic shock, burns or ery-
sipelas caused by group A Streptococci, elevated levels
of HBP have been documented [4-8]. The levels of HBP
were elevated up to 12 h prior to the clinical manifest-
ation of septic shock [5].
Pulmonary infections and septic infections are respon-
sible for more than a third of acute respiratory failure
leading to ICU admission [9]. In bacterial infections,
neutrophils become activated leading to the release of
HBP [10]. Filgrastim is a granulocyte colony stimulating
factor (G-CSF) which stimulates neutrophil production
in bone marrow as well as strengthens their functions,
such as phagocytosis and bacterial killing [11]. Increased
HBP –levels have been documented in several different
bacterial infections [4-6,12]. However, no clinical trial
has studied the effect of G-CSF on HBP –levels.
We hypothesized that increased number of circulating
neutrophils in response to G-CSF treatment would be
associated with increased HBP concentrations in plasma
compared to placebo. Accordingly, we analyzed the HBP
concentrations in critically ill patients with acute respira-
tory failure who participated in a prospective, rando-
mised, double-blind study of G-CSF vs. placebo.
Methods
This is a study of plasma HBP –levels of a previously
published trial of G-CSF in critically ill patients [13].
The study was approved by the Ethics Committee of De-
partment of Anaesthesiology in Helsinki University Cen-
tral Hospital. The notice to the Finnish National Agency
for Medicines was submitted 60 days before the initi-
ation of the study as required by Finnish legislation.
Informed consent was obtained from the study patients
or from a close relative.
Study patients
During a 16 –month period from February 1997 to June
1998 altogether 636 patients were admitted to the mixed
10 –bed ICU. 59 consecutive patients were included into
the study. The inclusion criteria were 1. age >18 years, 2.admission <12 h before study inclusion, 3. intubation
<48 h of study inclusion, 4. expected ICU stay >48 h, 5.
Informed consent signed. The exclusion criteria were 1.
age <18 years, 2. admission >12 h before study inclusion
3. Intubated >48 h before study inclusion, 4. expected
stay in ICU <48 h, 5. no informed consent, 6. pregnant
or nursing, 7. administration of filgrastim, sargramostin
or other biological response modifiers within 7 days, 8.
participation in another medicinal trial.
Study design
The study was a prospective, randomised, double-blind,
placebo-controlled trial of filgrastim in patients with acute
respiratory failure requiring intubation. The patients were
treated with subcutaneous injections of 300 micrograms
of filgrastim or corresponding placebo (1 ml of 0.9%
NaCl –solution) once daily for 7 days or until discharge
from the ICU. If the neutrophil count exceeded 50x109/L
filgrastim/placebo was administered every other day and if
neutrophil count exceeded 75x109/L filgrastim/placebo
was discontinued. The study personnel were blinded to
study patients’ leukocyte and neutrophil counts until the
data had been analyzed. Other intensive care treatments
were performed according to the written standard operat-
ing procedures of the ICU.
Blood samples were drawn at study entry (baseline),
day 4 and day 7 afterwards. The samples were taken be-
fore administration of the study drug. The sampling was
performed only during the ICU stay and if a patient was
discharged by day 7, blood collection was also discontin-
ued. The blood samples were drawn and placed immedi-
ately in ice and centrifuged at +4°C. The plasma was
stored in −70°C until further analysis. Total leukocyte
count and absolute neutrophil count were determined in
routine analysis of Helsinki University Central Hospital
laboratory. The plasma HBP was determined by
enzyme-linked immunosorbent assay as described earlier
[2]. The detection limit of the method was 0.25 ng/ml
and CV variance was <5%.
The primary endpoint of the main study were number
of adverse events, the number of patients developing
ARDS, disseminated intravascular coagulation or acute
renal failure during days 1–28, and changes in MOD
score [13]. For this substudy, the clinical data comprised
of APACHE II [14], SOFA -score [15,16], admission
diagnosis, and laboratory values for white blood cell
(WBC), neutrophil count and inflammatory mediators:
(Interleukin (IL)-6, Interleukin (IL)-10, soluble E-selectin
(sE-selectin) and soluble Interleukin 2 receptor (sIL-2R)
from baseline and day 3 [17].
Statistical analysis
The data are presented as median and interquartile ranges
(IQR) or absolute numbers and ranges, as appropriate.
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with Kolmorogov-Smirnov one-sample test. In case of
non-normal distribution, the parameters were transformed
to natural logarithm before analysis. The difference be-
tween groups is calculated by one-way analysis of variance
with a p value <0.05 considered statistically significant.
The correlations between parameters were calculated
from values transformed to natural logarithm. Intraclass
correlation coefficient (ICC) was used to examine the cor-
relation between HBP -levels, P/F –ratio, SOFA –score,
WBC and neutrophil count as well as inflammatory
mediators.
Results
Altogether 59 patients were included into the study, 30
in the filgrastim group and 29 in the placebo group. Due
to an error in the preparation of randomisation envel-
opes number 45 was omitted and only 59 patients were
randomised instead of the intended 60 patients. The
baseline characteristics of the patients are presented in
the Table 1.
The plasma HBP –concentrations, absolute neutrophil
counts and white blood cell counts at baseline, day 4 and
day 7 are presented in Figure 1 and Table 2. The plasma
concentrations of HBP in filgrastim and placebo groups
were similar at baseline, median [IQR] 23.6 ng/ml [13.9-
43.0 ng/ml] vs. 21.6 ng/ml [16.9-28.7 ng/ml], respectively
(p = 0.785). At day 4, the filgrastim group had significantly
higher HBP –concentrations when compared to placebo
group 25.1 ng/ml [17.7-35.5 ng/ml] vs. 13.9 ng/ml [12.0-
19.5 ng/ml], respectively (p < 0.05). At day 7, there was no
difference in HBP levels 15.9 ng/ml [12.6-20.7 ng/ml] vs.
17.8 ng/ml [13.6-20.9 ng/ml] in filgrastim and placebo
groups (p = 0.774), respectively.
The absolute neutrophil count and white blood cell
counts were similar in filgrastim and placebo groups at
baseline but at days 4 and 7 there were significant in-
crease in filgrastim group (p < 0.01 for both; Table 2).Table 1 Baseline characteristics of study population
Variable Controls (n = 29) Filgrastim (n = 30)
Age (yr) 52 (28–73) 45 (20–76)
Gender (F/M) 6/23 9/21
APACHE II 13 (3–28) 11 (2–19)
Admission diagnosis
Bacterial infection* 14 12
Inflammatory process** 6 6
Other 9 12
SOFA 9 (3–15) 8.5 (2–15)
APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequental
Organ Failure Assessment, median (range).
*Bacterial infection: pneumonia, blood culture positive sepsis,
meningitis, peritonitis.
**Inflammatory process: aspiration pneumonia, acute pancreatitis.The HBP/WBC –ratio was similar in both groups at
baseline, but at days 4 and 7, the ratio decreased more
in placebo group compared to filgrastim group. HBP/ab-
solute neutrophil count –ratio also decreased from base-
line in both groups, but the decrease was greater in
filgrastim group (Table 2).
In patients with septic shock vs. no septic shock, no dif-
ference in plasma HBP –concentrations could be detected
in any of the time points (baseline, 4 –day or 7 –day) re-
gardless of filgrastim treatment. The HBP –concentrations
were above 15 ng/ml in 44 of the 59 patients at baseline.
No correlations between HBP –concentrations and abso-
lute neutrophil count or P/F –ratio could be demonstrated
(Figure 2). The concentrations of HBP (baseline or day 4)
did not correlate with SOFA –score. No correlation of
HBP with inflammatory mediators IL-6 (p = 0.42), IL-10
(p = 0.44), or sIL-2R (p = 0.32) was found. A modest cor-
relation with sE-Sel was found (rho 0.275, p < 0.01).
Discussion
Our study was the first to assess HBP –levels in critically
ill patients receiving filgrastim or placebo in a controlled
study. The HBP –levels were similar in both treatment
groups at baseline, but differed at day 4. The difference
in HBP –levels did not persist to day 7, and HBP –con-
centrations did not correlate with absolute neutrophil
count or P/F –ratios.
The concentrations of HBP were elevated in both
groups already at the baseline samples. In healthy volun-
teers without infections and in patients with local infec-
tions only, the concentrations of HBP have been around
7 ng/ml compared to 24 ng/ml and 22 ng/ml in filgras-
tim and placebo groups at baseline, respectively [8].
These baseline concentrations were, however, lower than
those previously described for febrile patients at hospital
admission who later develop septic shock (42 ng/ml) or
severe sepsis (30 ng/ml) [5]. When compared to burn
patients or sepsis patients at ICU admission, the HBP –
levels were similar [4,7]. In our study population, all
patients had acute respiratory failure, but not all had
bacterial infection. HBP is released in systemic inflam-
matory reactions including sepsis, and a cut-off value of
15 ng/ml is found to have the best predictive value for
the development of septic shock [5]. In our study
patients 44 out of 59 exceeded this level at baseline even
though only 16 of the 59 patients were diagnosed as hav-
ing severe sepsis or septic shock.
HBP is an important mediator of bacterial infections
transforming to septic shock. In septic situations, HBP is
released from activated neutrophils by exocytosis of gran-
ule compartments. Filgrastim stimulates the production of
new neutrophils in bone marrow and enhances the ef-
fector functions of mature neutrophils [18]. As HBP is
released from activated neutrophils, the stimulation of
Figure 1 The concentrations (ng/ml; median, 95% CI) of HBP between patients receiving filgrastim 300 microgr/day or placebo for 7 days.
Kaukonen et al. BMC Infectious Diseases 2013, 13:51 Page 4 of 6
http://www.biomedcentral.com/1471-2334/13/51neutrophil production and function by filgrastim could
lead to increased secretion of HBP. In our study, the levels
of HBP were already elevated at baseline compared to
healthy volunteers or to patients with local infections only,
but not compared to febrile patients who develop septic
shock or severe sepsis. At day 4, there was a significant
difference in the HBP –levels between filgrastim and pla-
cebo groups. This seems to be caused by a decrease of
HBP –concentrations in placebo group rather than an in-
crease in HBP –concentrations of filgrastim group. Previ-
ously, in burn patients, the levels of HBP have decreased
to near-normal levels in 24–48 h after the ICU admission




HBP (ng/ml) 23.6 (13.9-43.0) 21.6 (16.9-28.7) 25.1
Neutrophil count (x109)/L 7.3 (4.0-11.1) 8.2 (3.6-12.8) 24.0
WBC count (x109)/L 9.1 (5.6-12.3) 12.1 (4.3-17.1) 27.2
HBP/WBC –ratio 2.9 (1.4-8.7) 2.8 (1.5-11.0) 0.9
HBP/Neutrophil –ratio 4.0 (1.7-9.8) 3.0 (1.6-12.5) 1.2
Median (IQR), WBC white blood cell count.
* p < 0.05 filgrastim vs. placebo.
† p < 0.001 filgrastim vs. placebo.
‡ Neutrophil count and WBC count from day 3.persist to day 7, at that day both groups had median
HBP –levels lower than that at baseline.
The correlation of HBP concentrations to WBC count
has been studied in previous trials [4,5]. In a subset of
patients with severe sepsis (with or without septic shock), a
positive correlation was found whereas no correlation was
found in burn patients. In our patients, no correlations be-
tween WBC and HBP –levels was found. In previous trials
the correlation between HBP –levels and absolute neutro-
phil count has not been studied. In our patient population,
however, no such correlation could be verified.
The M1 –protein mediated release of neutrophil gran-
ule contents is responsible for subsequent lung injuryand WBC in patients receiving daily filgrastim 300
Day 4‡ Day 7
grastim Placebo Filgrastim Placebo
(17.7-35.5)* 13.9 (12.0-19.5) 15.9 (12.6-20.7) 17.8 (13.6-20.9)
(14.6-32.8)† 9.4 (7.5-13.7) 27.1 (18.7-38.9)† 9.4 (6.1-12.0)
(17.6-36.0)† 12.1 (10.0-16.5) 29.7 (20.1-39.8)† 12.2 (14.9)
(0.6-1.7)* 0.7 (0.5-0.9) 1.6 (1.1-2.1) † 0.7 (0.7-1.0)
(0.7-2.2) 1.8 (1.3-2.4) 0.7 (0.5-1.2)* 1.7 (1.3-2.1)
Figure 2 The correlation of HBP –concentrations to P/F –ratio (left panel) and absolute neutrophil count (right panel).
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azurophilic/primary granule subsets, it is readily released
when neutrophils become activated [2,10]. Initially fil-
grastim was thought to have beneficial effects on the
outcome of critically ill patients with septic infections.
However, no mortality benefit could be shown in critic-
ally ill patients with pneumonia and severe sepsis or sep-
tic shock in a large randomised placebo-controlled trial
[20]. The worsening of pulmonary function and even the
development of acute respiratory distress syndrome
(ARDS) has been of concern in patients receiving filgras-
tim. As filgrastim treatment results in prolonged high
levels of HBP, this could have deleterious effects on pul-
monary capillary leakage and pulmonary function. In
our patients, the plasma concentrations of HBP did not
correlate with the P/F –ratios.
Our study had some limitations. The number of
patients was low and, accordingly, there is considerable
risk to type II error, i.e. not detecting a true difference
even though it is present. Due to the limited number of
patients in this randomized pilot study, we were not able
to analyze HBP –levels in subgroups of patients with
bacterial infections, other inflammatory processes, or
with non-infectious causes of acute respiratory failure.
Second, the sampling was not primarily designed for
measurements of plasma HBP –concentrations, but ra-
ther to show the change in organ failure score before
and after the intervention. As the decline in HBP occurs
within days in critically ill patients [4], more frequent
sampling would have been better to detect the maximal
effect of filgrastim. Thus, it is possible that filgrastim
may have caused a temporary increase in HBP –levels,
and we were not able to detect it. Finally, as the primary
study was performed already in 1997, the blood samples
have been conserved in −70° over time. This may havehad effect on the HBP levels. If degradation of HBP had
occurred, it can be suspected that the degradation of
HBP would have occurred to the same degree in both
treatment groups.
Conclusions
Filgrastim treatment is associated with increased circu-
lating HBP levels compared to placebo, but the absolute
neutrophil count or the degree of oxygenation failure
did not correlate with the observed plasma HBP –
concentrations.
Key messages
 Plasma levels of heparin-binding protein (HBP) were
elevated in critically ill patients with acute
respiratory failure requiring intubation at baseline.
 A significant decrease in HBP –levels in placebo –
treated patients was observed at day 4.
 HBP –levels did not correlate with absolute white
blood cell or neutrophil counts.
 HBP –levels did not correlate with worsening of
oxygenation measured by P/F –ratio.
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